Steward Partners Investment Advisory’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Steward Partners Investment Advisory’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-147	Closed	-$272	–	4155
2024 Q3	$272	Hold	147	–	–	﹤0.01%	3639
2024 Q2	$1.27K	Buy	+147	New	+$1.3K	﹤0.01%	3363

Other funds holding TLIS

SAM

Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return

Steward Partners Investment Advisory's TLIS Position: Q4 2024 in Review

Steward Partners Investment Advisory sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2024, closing a stake of 147 shares — an estimated $272 sold.

Steward Partners Investment Advisory first reported a position in TLIS in Q2 2024 and held it in 2 quarters. The position peaked at $1.27K in Q2 2024. 1 fund tracked by Wall St. Rank holds TLIS as of Q4 2024.

Steward Partners Investment Advisory reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2024 after selling out during the quarter.
Steward Partners Investment Advisory sold 147 Talis Biomedical Corporation Common Stock shares in Q4 2024, an estimated $272.
Steward Partners Investment Advisory first reported a position in Talis Biomedical Corporation Common Stock in Q2 2024 and held it in 2 quarters.
Steward Partners Investment Advisory's Talis Biomedical Corporation Common Stock position peaked at $1.27K in Q2 2024.
1 fund tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2024, filed 6 Feb 2025.